研究领域
Dr. Peter Forsyth is chairman of the Neuro-Oncology Program at Moffitt Cancer Center and professor of oncology at the University of South Florida. An internationally recognized neuro-oncology physician-scientist, Dr. Forsyth joined Moffitt in 2011 after more than a decade with the Tom Baker Cancer Centre at the University of Calgary in Canada, where he was a professor of oncology and neurosciences, as well as associate director of research.
Dr. Forsyth has a strong interest in malignant, invasive glioma brain tumors. He is currently investigating several tumor-inhibiting agents in Phase I clinical trials. One of his first priorities at Moffitt is to develop a neural tumor stem cell lab to expand research opportunities in novel therapeutic cancer-fighting drugs. Currently, he has 10 active grants funding his studies.
Dr. Forsyth received his medical degree at McMasters University in Ontario, completed a neurology residency at the Mayo Clinic and then a fellowship at Memorial Sloan-Kettering Cancer Center. Before joining Moffitt, he was interim director of the Southern Alberta Cancer Research Institute. Dr. Forsyth is the recipient of numerous awards and honors, including receiving the Canadian Cancer Society Award of Excellence in Medicine & Health twice. In 2006, he was a guest professor at Second Hospital of Shangdong Province in China.
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Sahebjam S, Forsyth PA, Smalley KS, Tran ND. Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies. Cancer Control. 2017 Jan;24(1):42-46. Pubmedid: 28178711.
Smalley KS, Fedorenko IV, Kenchappa R, Sahebjam S, Forsyth PA. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer. 2016 Sep;139(6):1195-1201. Pubmedid: 27084046. Pmcid: PMC4939138.
Egan KM, Nabors LB, Thompson ZJ, Rozmeski CM, Anic GA, Olson JJ, LaRocca RV, Chowdhary SA, Forsyth PA, Thompson RC. Analgesic use and the risk of primary adult brain tumor. Eur J Epidemiol. 2016 Sep;31(9):917-925. Pubmedid: 26894804. Pmcid: PMC4991947.
Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, McIntosh L, Caceres G, Magliocco A, Etame A, Harbour JW, Smalley KS, Forsyth PA. A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. Melanoma Res. 2016 Oct;26(5):481-486. Pubmedid: 27285292.
Pisklakova A, McKenzie B, Zemp F, Lun X, Kenchappa RS, Etame AB, Rahman MM, Reilly K, Pilon-Thomas S, McFadden G, Kurz E, Forsyth PA. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. Neurooncol. 2016 Mar. Pubmedid: 26962017. Pmcid: PMC4933479.
Wang D, Berglund A, Kenchappa RS, Forsyth PA, Mulé JJ, Etame AB. BIRC3 is a novel driver of therapeutic resistance in Glioblastoma. Sci Rep. 2016 Feb;6:21710. Pubmedid: 26888114. Pmcid: PMC4757860.
Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016 Dec;27(12):2288-2294. Pubmedid: 27637745.
Prabhu A, Sarcar B, Miller CR, Kim SH, Nakano I, Forsyth P, Chinnaiyan P. Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Neurooncol. 2015 Sep;17(9):1220-1230. Pubmedid: 25712957. Pmcid: PMC4588752.
Baskin R, Woods NT, Mendoza-Fandiño G, Forsyth P, Egan KM, Monteiro AN. Functional analysis of the 11q23.3 glioma susceptibility locus implicates PHLDB1 and DDX6 in glioma susceptibility. Sci Rep. 2015 Nov;5:17367. Pubmedid: 26610392. Pmcid: PMC4661592.
Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, Sarangkasiri S, Chinnaiyan P, Forsyth PA, Etame AB, Rao NG. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol. 2015 Mar;122(1):121-126. Pubmedid: 25519302.
Lawn S, Krishna N, Pisklakova A, Qu X, Fenstermacher DA, Fournier M, Vrionis FD, Tran N, Chan JA, Kenchappa RS, Forsyth PA. Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. J Biol Chem. 2015 Feb;290(6):3814-3824. Pubmedid: 25538243. Pmcid: PMC4319045.
Dalia S, Price S, Forsyth P, Sokol L, Jaglal M. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?. Leuk Lymphoma. 2015 Feb;56(2):500-502. Pubmedid: 24882264.
McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neurooncol. 2015 Aug;17(8):1086-1094. Pubmedid: 25605818. Pmcid: PMC4490869.
Forsyth PA, Krishna N, Lawn S, Valadez JG, Qu X, Fenstermacher DA, Fournier M, Potthast L, Chinnaiyan P, Gibney GT, Zeinieh M, Barker PA, Carter BD, Cooper MK, Kenchappa RS. p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells. J Biol Chem. 2014 Mar;289(12):8067-8085. Pubmedid: 24519935. Pmcid: PMC3961639.
Anic GM, Madden MH, Nabors LB, Olson JJ, Larocca RV, Thompson ZJ, Pamnani SJ, Forsyth PA, Thompson RC, Egan KM. Reproductive factors and risk of primary brain tumors in women. J Neurooncol. 2014 Jun;118(2):297-304. Pubmedid: 24700240. Pmcid: PMC4048769.
Sarkar S, Döring A, Zemp FJ, Silva C, Lun X, Wang X, Kelly J, Hader W, Hamilton M, Mercier P, Dunn JF, Kinniburgh D, van Rooijen N, Robbins S, Forsyth P, Cairncross G, Weiss S, Yong VW. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci. 2014 Jan;17(1):46-55. Pubmedid: 24316889.
Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA. Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon. PLoS One. 2014 Jan;8(6):e65801. Pubmedid: 23762429. Pmcid: PMC3675064.
Ogbomo H, Zemp FJ, Lun X, Zhang J, Stack D, Rahman MM, McFadden G, Mody CH, Forsyth PA. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS One. 2014 Feb;8(6):e66825. Pubmedid: 23762498. Pmcid: PMC3677932.
Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. Cancer Res. 2014 Dec;74(24):7260-7273. Pubmedid: 25336188. Pmcid: PMC4281961.
Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr;99(4):450-456. Pubmedid: 24584873.
京公网安备 11010802027423号